Catalent is cutting more roles at its gene therapy manufacturing facility in Harmans, Maryland. This round of layoffs will affect 93 employees at the Harmans facility and three more in nearby Baltimore.

Gilead penned a potential $1.5 billion synthetic lethality deal with a Chinese biotech. A cell therapy company could end a one-year-plus biotech IPO drought in Tokyo. Novo Nordisk faces increased GLP-1 competition in China. And more.

After the pharmaceutical industry spent much of the past year safeguarding its businesses against the threat of U.S. import tariffs, a new Supreme Court ruling now waylays the Trump administration’s trade agenda—at least in part.

The new proposed board members come after an extraordinary general meeting last fall saw a significant change in leadership.

After manufacturing the antibiotic Rocephin for four decades—and developing it into one of the company’s first blockbuster medicines—Roche is looking to divest the treatment and its production facility near its headquarters in Switzerland.

AstraZeneca has secured a key regulatory win in its effort to reclaim the lead in the BTK inhibitor market, with the FDA approving its Calquence plus Venclexta as the first all-oral, fixed-duration regimen for first-line chronic lymphocytic leukemia.